SEC 13F Intelligence

Managers / Q2 2021 · view latest →

First Light Asset Management, LLC

CIK 0001600004 · 3300 EDINBOROUGH WAY, SUITE 201, EDINA, MN, 55435 · 952-831-6500

Reported Value
$1.7B
Q2 2021
Positions
79
Filings on Record
30
2019–present window
Filed
Aug 13, 2021
original filing

Summary

First Light Asset Management, LLC reported $1.7B in U.S.-listed holdings across 79 positions for Q2 2021.

Its largest position, SPNEUSD, represents 7.4% of the portfolio.

Compared with Q1 2021, the fund opened 7 new positions and exited 5.

Portfolio Metrics

Turnover
+6.9%
vs prior filed quarter
Top-10 Concentration
+44.6%
share of reported value
Largest Position
+7.4%
Seaspine
New / Exited
7 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $627MQ4 ’18Q1 ’19: $770MQ2 ’19: $720MQ3 ’19: $662MQ4 ’19: $782MQ4 ’19Q1 ’20: $586MQ2 ’20: $858MQ3 ’20: $976MQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.5BQ2 ’21: $1.7BQ3 ’21: $1.5BQ4 ’21: $1.4BQ4 ’21Q1 ’22: $1.1BQ2 ’22: $859MQ3 ’22: $988MQ4 ’22: $1.1BQ4 ’22Q1 ’23: $1.1BQ2 ’23: $1.3BQ3 ’23: $1.1BQ4 ’23: $1.2BQ4 ’23Q1 ’24: $1.3BQ2 ’24: $1.1BQ3 ’24: $1.2BQ4 ’24: $1.0BQ4 ’24Q1 ’25: $876MQ2 ’25: $771MQ3 ’25: $1.1BQ4 ’25: $1.3BQ4 ’25Q1 ’26: $1.1Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.3%Other: 13.9%ADR: 4.1%ETP: 0.7%
  • Common Stock · 81.3% · $1.4B
  • Other · 13.9% · $231M
  • ADR · 4.1% · $69M
  • ETP · 0.7% · $11M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RLAYRELAY THERAPEUTICS INCNEW+390.6K390.6K+$14M$14M
SPDR S&P BIOTECH ETFNEW+82.7K82.7K+$11M$11M
MIROMATRIX MEDICAL INCNEW+475.0K475.0K+$6M$6M
ANNXANNEXON BIOSCIENCES INCNEW+206.1K206.1K+$5M$5M
FATEFATE THERAPEUTICS INCNEW+15.4K15.4K+$1M$1M
HUMHUMANA INCNEW+1.1K1.1K+$473,000$473,000
TAKEDA PHARMACEUTICAL CONEW+25.6K25.6K+$431,000$431,000
TURNING POINT THERAPEUTICSADDED+336.9K395.8K+$25M$31M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPNEUSDSEASPINE HOLDINGS CORPhistory →Common Stocks7.37%$123M5.99M
2PROTHENA CORPORATION PLCCommon Stocks5.95%$99M1.93M
3HALOHALOZYME THERAPEUTICS INChistory →Common Stocks5.59%$93M2.05M
4CDNACAREDX INChistory →Common Stocks4.92%$82M896.3K
5MODNEURMODEL N INChistory →Common Stocks4.44%$74M2.16M
6ATRCATRICURE INChistory →Common Stocks3.68%$61M772.8K
7OMCLOMNICELL INChistory →Common Stocks3.46%$58M381.1K
8NEONEOGENOMICS INChistory →Common Stocks3.11%$52M1.15M
9TNDMTANDEM DIABETES CARE INChistory →Common Stocks3.09%$51M528.6K
10CUTREURCUTERA INChistory →Common Stocks2.99%$50M1.02M
11AXGNAXOGEN INChistory →Common Stocks2.88%$48M2.22M
12HCATHEALTH CATALYST INChistory →Common Stocks2.63%$44M789.4K
13ARNAEURARENA PHARMACEUTICALS INChistory →Common Stocks2.53%$42M617.1K
14OPRXOPTIMIZERX CORPhistory →Common Stocks2.47%$41M664.8K
15IM8NINSMED INChistory →Common Stocks2.37%$39M1.39M
16ALDXALDEYRA THERAPEUTICS INChistory →Common Stocks2.36%$39M3.47M
17ARWRARROWHEAD PHARMACEUTICALS INChistory →Common Stocks2.31%$39M465.6K
18SUTRO BIOPHARMA INCCommon Stocks2.31%$39M2.07M
19XENTEURINTERSECT ENT INChistory →Common Stocks2.27%$38M2.21M
20KRYSKRYSTAL BIOTECH INChistory →Common Stocks2.15%$36M526.6K
21GKOSGLAUKOS CORPORATIONhistory →Common Stocks2.08%$35M409.1K
22YMABUSDY-MABS THERAPEUTICS INChistory →Common Stocks1.93%$32M950.2K
23KARUNA THERAPEUTICS INCCommon Stocks1.88%$31M274.8K
24TURNING POINT THERAPEUTICSCommon Stocks1.85%$31M395.8K
25TEVATEVA PHARMACEUTICAL INDhistory →Common Stocks1.77%$29M2.97M
26ATECALPHATEC HOLDINGS INChistory →Common Stocks1.62%$27M1.76M
27KRMDREPRO-MED SYSTEMS INChistory →Common Stocks1.51%$25M5.42M
28GMABGENMAB AShistory →Common Stocks1.49%$25M607.0K
29STIMNEURONETICS INChistory →Common Stocks1.41%$23M1.46M
30SIBNSI-BONE INChistory →Common Stocks1.33%$22M704.2K
31RAREULTRAGENYX PHARMACEUTICAL INChistory →Common Stocks1.31%$22M229.2K
32AXNX*AXONICS MODULATION TECHNOLOGIEShistory →Common Stocks1.27%$21M332.9K
33MEI PHARMA INCCommon Stocks1.20%$20M7.00M
34CDXSCODEXIS INChistory →Common Stocks0.96%$16M703.2K
35KIDSORTHOPEDIATRICS CORPhistory →Common Stocks0.87%$15M229.9K
36RLAYRELAY THERAPEUTICS INChistory →Common Stocks0.86%$14M390.6K
37ITMRITAMAR MEDICAL LTDhistory →Common Stocks0.83%$14M586.4K
38APTOSE BIOSCIENCES INCCommon Stocks0.82%$14M4.12M
39AKUMIN INCCommon Stocks0.67%$11M3.56M
40SPDR S&P BIOTECH ETFCommon Stocks0.67%$11M82.7K
41TCRRUSDTCR2 THERAPEUTICS INChistory →Common Stocks0.63%$11M644.2K
42JYNTTHE JOINT CORPCommon Stocks0.59%$10M116.8K
43QDEL*QUIDEL CORPCommon Stocks0.56%$9M72.4K
44INVITAE CORPORATIONCommon Stocks0.52%$9M255.3K
45MRVIMARAVAI LIFE SCIENCESCommon Stocks0.51%$8M202.1K
46MIROMATRIX MEDICAL INCCommon Stocks0.33%$6M475.0K
47ANNXANNEXON BIOSCIENCES INCCommon Stocks0.28%$5M206.1K
48SLPSIMULATIONS PLUS INCCommon Stocks0.25%$4M75.8K
49LHCGUSDLHC GROUP INCCommon Stocks0.19%$3M15.4K
50SIENUSDSIENTRA INCCommon Stocks0.16%$3M325.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.1B35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.3B33Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.1B41Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$771M38Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$876M37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.0B36Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.2B38Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.1B44Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.3B50May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.2B75Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$1.1B75Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.3B79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.1B74May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.1B74Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$988M71Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$859M71Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.1B75May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.4B79Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.5B83Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.7B79Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.5B77May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B74Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$976M60Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$858M60Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$586M64May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$782M69Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$662M71Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$720M73Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$770M63May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$627M59Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.